Cargando…

Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes

Sclerostin (Scl) is an osteoblast-inhibiting glycoprotein that is secreted mainly by osteocytes and is regulated by hormonal changes and skeletal loading. Decreased physical function and high serum Scl concentrations have been reported in chronic renal failure patients but little is known to date ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Medeiros, Maria Carolina, Rocha, Natalia, Bandeira, Elba, Dantas, Isabel, Chaves, Conceição, Oliveira, Mario, Bandeira, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035555/
https://www.ncbi.nlm.nih.gov/pubmed/32095286
http://dx.doi.org/10.1155/2020/4596920
_version_ 1783500082981634048
author Medeiros, Maria Carolina
Rocha, Natalia
Bandeira, Elba
Dantas, Isabel
Chaves, Conceição
Oliveira, Mario
Bandeira, Francisco
author_facet Medeiros, Maria Carolina
Rocha, Natalia
Bandeira, Elba
Dantas, Isabel
Chaves, Conceição
Oliveira, Mario
Bandeira, Francisco
author_sort Medeiros, Maria Carolina
collection PubMed
description Sclerostin (Scl) is an osteoblast-inhibiting glycoprotein that is secreted mainly by osteocytes and is regulated by hormonal changes and skeletal loading. Decreased physical function and high serum Scl concentrations have been reported in chronic renal failure patients but little is known to date about the differences between diabetic and non-diabetic patients on hemodialysis who are susceptible to both sarcopenia and bone fragility. Objective.To determine the prevalence of sarcopenia and its association with serum Scl concentrations and metabolic parameters in 92 patients on hemodialysis. Anthropometric data and physical performance were evaluated in this study. Blood samples were collected for Scl, glucose, cholesterol, triglycerides, calcium, phosphate, PTH, and 25 OH-vitamin D measurements. Lean mass was evaluated using multifrequency electro-bioimpedance after dialysis session. Results. Mean age was 63.3 ± 13.6 years, 63% of patients were male, and 44.6% had diabetes. Mean body mass index (BMI) was higher in diabetics (26.6 ± 5.2 vs. 24.1 ± 3.7; p=0.01) and there were no differences in gait speed and handgrip strength between diabetic and non-diabetic subjects. A low skeletal muscle mass index (SMI) was identified in 65.2% of the participants, and among them 76.7% were men and 36.7% were diabetics. Mean serum Scl was 86.9 ± 39.0 pmol/L, which was higher in men (94.6 ± 41.7; p=0.017), in those individuals with low SMI (94.9 ± 40.7; p < 0.001), and in diabetics (97.2 ± 46.6; p < 0.003). After multivariate analysis and adjustments for potential confounders, high serum Scl was independently associated with low SMI and with the presence of diabetes. The following variables correlated positively with diabetes: blood pressure; BMI; waist circumference; waist/hip ratio; plasma glucose; serum Scl; and fat mass. Conclusions. We found higher serum Scl concentrations in hemodialysis patients with diabetes and these were inversely related to muscle mass.
format Online
Article
Text
id pubmed-7035555
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-70355552020-02-24 Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes Medeiros, Maria Carolina Rocha, Natalia Bandeira, Elba Dantas, Isabel Chaves, Conceição Oliveira, Mario Bandeira, Francisco Int J Nephrol Research Article Sclerostin (Scl) is an osteoblast-inhibiting glycoprotein that is secreted mainly by osteocytes and is regulated by hormonal changes and skeletal loading. Decreased physical function and high serum Scl concentrations have been reported in chronic renal failure patients but little is known to date about the differences between diabetic and non-diabetic patients on hemodialysis who are susceptible to both sarcopenia and bone fragility. Objective.To determine the prevalence of sarcopenia and its association with serum Scl concentrations and metabolic parameters in 92 patients on hemodialysis. Anthropometric data and physical performance were evaluated in this study. Blood samples were collected for Scl, glucose, cholesterol, triglycerides, calcium, phosphate, PTH, and 25 OH-vitamin D measurements. Lean mass was evaluated using multifrequency electro-bioimpedance after dialysis session. Results. Mean age was 63.3 ± 13.6 years, 63% of patients were male, and 44.6% had diabetes. Mean body mass index (BMI) was higher in diabetics (26.6 ± 5.2 vs. 24.1 ± 3.7; p=0.01) and there were no differences in gait speed and handgrip strength between diabetic and non-diabetic subjects. A low skeletal muscle mass index (SMI) was identified in 65.2% of the participants, and among them 76.7% were men and 36.7% were diabetics. Mean serum Scl was 86.9 ± 39.0 pmol/L, which was higher in men (94.6 ± 41.7; p=0.017), in those individuals with low SMI (94.9 ± 40.7; p < 0.001), and in diabetics (97.2 ± 46.6; p < 0.003). After multivariate analysis and adjustments for potential confounders, high serum Scl was independently associated with low SMI and with the presence of diabetes. The following variables correlated positively with diabetes: blood pressure; BMI; waist circumference; waist/hip ratio; plasma glucose; serum Scl; and fat mass. Conclusions. We found higher serum Scl concentrations in hemodialysis patients with diabetes and these were inversely related to muscle mass. Hindawi 2020-02-10 /pmc/articles/PMC7035555/ /pubmed/32095286 http://dx.doi.org/10.1155/2020/4596920 Text en Copyright © 2020 Maria Carolina Medeiros et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Medeiros, Maria Carolina
Rocha, Natalia
Bandeira, Elba
Dantas, Isabel
Chaves, Conceição
Oliveira, Mario
Bandeira, Francisco
Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes
title Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes
title_full Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes
title_fullStr Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes
title_full_unstemmed Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes
title_short Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes
title_sort serum sclerostin, body composition, and sarcopenia in hemodialysis patients with diabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035555/
https://www.ncbi.nlm.nih.gov/pubmed/32095286
http://dx.doi.org/10.1155/2020/4596920
work_keys_str_mv AT medeirosmariacarolina serumsclerostinbodycompositionandsarcopeniainhemodialysispatientswithdiabetes
AT rochanatalia serumsclerostinbodycompositionandsarcopeniainhemodialysispatientswithdiabetes
AT bandeiraelba serumsclerostinbodycompositionandsarcopeniainhemodialysispatientswithdiabetes
AT dantasisabel serumsclerostinbodycompositionandsarcopeniainhemodialysispatientswithdiabetes
AT chavesconceicao serumsclerostinbodycompositionandsarcopeniainhemodialysispatientswithdiabetes
AT oliveiramario serumsclerostinbodycompositionandsarcopeniainhemodialysispatientswithdiabetes
AT bandeirafrancisco serumsclerostinbodycompositionandsarcopeniainhemodialysispatientswithdiabetes